Literature DB >> 31939222

A Phthalocyanine-ortho-Carborane Conjugate for Boron Neutron Capture Therapy: Synthesis, Physicochemical Properties, and in vitro Tests.

Ilgın Nar1, Silva Bortolussi2,3, Ian Postuma2, Armağan Atsay1, Ekin Berksun1, Elisa Viola4, Cinzia Ferrari5, Laura Cansolino5, Giampaolo Ricciardi6, Maria Pia Donzello4, Esin Hamuryudan1.   

Abstract

Boronated molecular systems can be applied to boron neutron capture therapy (BNCT). Among these systems, carborane-containing phthalocyanines (Pcs) are the most promising BNCT agents. Herein we report the new zinc (II) complex of the hexacationic Pc 6, which has been obtained as iodide salt through quaternization of the neutral precursor with methyl iodide. Compound 6 was synthesized over a sequence of four steps. The complex, and its precursors as well, were characterized by a combination of spectroscopic techniques, and their structures assessed by 1 H, 13 C, 11 B, and two-dimensional NMR spectroscopy experiments. Together with a marked tendency to aggregate, 6 showed appreciable solubility in water. Singlet oxygen quantum yield (ΦΔ ) of 0.38, and fluorescence quantum yield (ΦF ) of 0.13 were obtained for 6 in a DMF solution. The complex proved to be very effective in enriching UMR-106 cells with 10 B, showing very good performance even in case of very low concentrations exposure, i. e. 1 ppm, that moreover resulted in a mild cytotoxic effect. Such a feature can be related to the polycationic nature of the complex, and hence to the well-known propensity of positively charged species to enter the cellular membrane or to adhere to its external surface.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  boron neutron capture therapy; cancer; carboranes; photodynamic therapy; phthalocyanines

Year:  2019        PMID: 31939222     DOI: 10.1002/cplu.201800560

Source DB:  PubMed          Journal:  Chempluschem        ISSN: 2192-6506            Impact factor:   2.863


  2 in total

Review 1.  Carboranes as unique pharmacophores in antitumor medicinal chemistry.

Authors:  Yu Chen; Fukuan Du; Liyao Tang; Jinrun Xu; Yueshui Zhao; Xu Wu; Mingxing Li; Jing Shen; Qinglian Wen; Chi Hin Cho; Zhangang Xiao
Journal:  Mol Ther Oncolytics       Date:  2022-01-10       Impact factor: 7.200

2.  Ruthenium carboranyl complexes with 2,2'-bipyridine derivatives for potential bimodal therapy application.

Authors:  Ricardo G Teixeira; Fernanda Marques; M Paula Robalo; Xavier Fontrodona; M Helena Garcia; Simonetta Geninatti Crich; Clara Viñas; Andreia Valente
Journal:  RSC Adv       Date:  2020-04-23       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.